CN100457751C - 苯并吡喃酮化合物,其组合物,以及治疗或预防癌症的方法 - Google Patents

苯并吡喃酮化合物,其组合物,以及治疗或预防癌症的方法 Download PDF

Info

Publication number
CN100457751C
CN100457751C CNB2003801043358A CN200380104335A CN100457751C CN 100457751 C CN100457751 C CN 100457751C CN B2003801043358 A CNB2003801043358 A CN B2003801043358A CN 200380104335 A CN200380104335 A CN 200380104335A CN 100457751 C CN100457751 C CN 100457751C
Authority
CN
China
Prior art keywords
alkyl
compound
cancer
tumor
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2003801043358A
Other languages
English (en)
Chinese (zh)
Other versions
CN1717405A (zh
Inventor
G·弗里德曼
J·麦基
J·赖特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Signal Pharmaceuticals LLC
Original Assignee
Signal Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signal Pharmaceuticals LLC filed Critical Signal Pharmaceuticals LLC
Publication of CN1717405A publication Critical patent/CN1717405A/zh
Application granted granted Critical
Publication of CN100457751C publication Critical patent/CN100457751C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
CNB2003801043358A 2002-10-15 2003-10-15 苯并吡喃酮化合物,其组合物,以及治疗或预防癌症的方法 Expired - Fee Related CN100457751C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US41846902P 2002-10-15 2002-10-15
US60/418,469 2002-10-15
US10/685,722 2003-10-14
US10/685,722 US7091235B2 (en) 2002-10-15 2003-10-14 Benzopyranone compounds, compositions thereof, and methods for treating or preventing cancer

Publications (2)

Publication Number Publication Date
CN1717405A CN1717405A (zh) 2006-01-04
CN100457751C true CN100457751C (zh) 2009-02-04

Family

ID=32110155

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2003801043358A Expired - Fee Related CN100457751C (zh) 2002-10-15 2003-10-15 苯并吡喃酮化合物,其组合物,以及治疗或预防癌症的方法

Country Status (13)

Country Link
US (3) US7091235B2 (enExample)
EP (1) EP1556374A4 (enExample)
JP (1) JP2006515275A (enExample)
KR (1) KR20050072764A (enExample)
CN (1) CN100457751C (enExample)
AU (1) AU2003286441A1 (enExample)
BR (1) BR0315400A (enExample)
CA (1) CA2502064A1 (enExample)
IL (1) IL168059A0 (enExample)
MX (1) MXPA05003909A (enExample)
NZ (1) NZ539675A (enExample)
WO (1) WO2004035002A2 (enExample)
ZA (1) ZA200503026B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7091235B2 (en) * 2002-10-15 2006-08-15 Signal Pharmaceuticals, Llc Benzopyranone compounds, compositions thereof, and methods for treating or preventing cancer
AU2004266233A1 (en) * 2003-08-13 2005-03-03 Amgen, Inc. Melanin concentrating hormone receptor antagonist
CA2534428A1 (en) * 2003-08-13 2005-03-03 Paul A. Tempest Melanin concentrating hormone receptor antagonists
WO2005028472A1 (en) * 2003-09-15 2005-03-31 Signal Pharmaceuticals, Llc Benzopyranone compounds, compositions thereof, and methods of treatment therewith
JP2008528495A (ja) * 2005-01-21 2008-07-31 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ イオンチャンネル開口薬としての新規なクマリン誘導体
AU2006262190A1 (en) * 2005-06-24 2007-01-04 Signal Pharmaceuticals, Llc. Benzopyranone compounds for treating cancer

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US633155A (en) 1898-02-23 1899-09-19 William W Ramsay Fence-repairing tool.
US5633155A (en) * 1992-08-19 1997-05-27 Jinro Limited Expression vector for phytolacca antiviral protein and process for preparing transgenic plant transformed therewith
US6291456B1 (en) * 1998-12-30 2001-09-18 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
US6444688B1 (en) * 1995-06-07 2002-09-03 Eli Lilly And Company Compounds and compositions with nitrogen-containing non-basic side chains
US6620838B1 (en) * 2002-04-19 2003-09-16 Signal Pharmaceuticals, Inc. Benzopyrazone compounds, compositions thereof, and methods of treatment therewith

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6331562B1 (en) * 1998-12-30 2001-12-18 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
JP2002533456A (ja) * 1998-12-30 2002-10-08 シグナル ファーマシューティカルズ， インコーポレイテッド エストロゲン受容体のモジュレートを行うための化合物および方法
KR20020075388A (ko) 1999-12-30 2002-10-04 시그널 파머슈티컬스 인크 에스트로겐 수용체의 조절 화합물 및 조절 방법
US7148252B2 (en) * 2001-10-03 2006-12-12 Signal Pharmaceuticals, Llc Use of benzopyranones for treating or preventing a primary brain cancer or a brain metastasis
CN100436440C (zh) * 2002-04-19 2008-11-26 信号药品公司 苯并吡喃酮化合物、其组合物以及其治疗方法
US7091235B2 (en) * 2002-10-15 2006-08-15 Signal Pharmaceuticals, Llc Benzopyranone compounds, compositions thereof, and methods for treating or preventing cancer

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US633155A (en) 1898-02-23 1899-09-19 William W Ramsay Fence-repairing tool.
US5633155A (en) * 1992-08-19 1997-05-27 Jinro Limited Expression vector for phytolacca antiviral protein and process for preparing transgenic plant transformed therewith
US6444688B1 (en) * 1995-06-07 2002-09-03 Eli Lilly And Company Compounds and compositions with nitrogen-containing non-basic side chains
US6291456B1 (en) * 1998-12-30 2001-09-18 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
US6620838B1 (en) * 2002-04-19 2003-09-16 Signal Pharmaceuticals, Inc. Benzopyrazone compounds, compositions thereof, and methods of treatment therewith

Also Published As

Publication number Publication date
US7091235B2 (en) 2006-08-15
KR20050072764A (ko) 2005-07-12
US20060194866A1 (en) 2006-08-31
WO2004035002A2 (en) 2004-04-29
NZ539675A (en) 2006-10-27
ZA200503026B (en) 2006-11-29
JP2006515275A (ja) 2006-05-25
US20040225005A1 (en) 2004-11-11
IL168059A0 (en) 2009-02-11
US7589119B2 (en) 2009-09-15
EP1556374A2 (en) 2005-07-27
AU2003286441A1 (en) 2004-05-04
BR0315400A (pt) 2005-08-16
MXPA05003909A (es) 2005-09-30
US7358274B2 (en) 2008-04-15
CN1717405A (zh) 2006-01-04
CA2502064A1 (en) 2004-04-29
WO2004035002A3 (en) 2004-08-26
US20080146648A1 (en) 2008-06-19
EP1556374A4 (en) 2007-12-19

Similar Documents

Publication Publication Date Title
TWI542349B (zh) 利用３－（５－胺基－２－甲基－４－氧基－４ｈ－喹唑啉－３－基）－六氫吡啶－２，６－二酮治療癌症之方法
TWI509247B (zh) 利用雷那度胺（ｌｅｎａｌｉｄｏｍｉｄｅ）治療非霍奇金氏淋巴瘤之方法及作為預測子之基因及蛋白質生物標記
US7067249B2 (en) Inhibition of hepatitis B virus (HBV) replication by RNA interference
CN103142594A (zh) 使用3-(4-氨基-1-氧代-1,3-二氢-异吲哚-2-基)-哌啶-2,6-二酮治疗某些白血病的方法
CN108245518A (zh) 利用3-(4-((4-(吗啉代甲基)苯甲基)氧基)-1-氧代异二氢吲哚-2-基)哌啶-2,6- 二酮治疗癌症的方法
EP2455378A1 (en) Carbazole and carboline derivatives, and preparation and therapeutic applications thereof
US20140343051A1 (en) Methods to modulate acute myeloid leukemia stem/progenitor cell expansion and/or differentiation
TWI732084B (zh) 治療atg4相關病症的方法
US20200069677A1 (en) Markers for personalized cancer treatment with lsd1 inhibitors
US7589119B2 (en) Methods for treating or preventing metastatic cancer using benzopyranone compounds
US7247646B2 (en) Benzopyranone compounds, compositions thereof, and methods of treatment therewith
CN109069470A (zh) 特定苯并二氢呋喃类木脂素于抑制乳癌细胞转移之用途
US20140194472A1 (en) Vitamin d receptor-coregulator inhibitors
WO2004065572A2 (en) Proteic binding partners of tctp and methods of modulating tumor reversion or cell apoptosis
KR100898330B1 (ko) 항암성을 갖는 새로운 플라보노이드 유도체 7-ｏ-(3-벤질옥시프로필)-5,4' -ｏ-디메틸-아피제닌, 그 제법 및 그것을 포함하는 항암 조성물
US20070191343A1 (en) 4-((4-(2-Azaperhydroepinylethoxy)phenyl)methyl)-3-2(2,4-dichlorophenyl)-7-hydroxychromen-2-one, pharmaceutically acceptable salts thereof and methods of use therewith
WO2008073304A9 (en) Cancer treatment methods
KR20100134966A (ko) 4'-ｏ-글루코스-루테올린의 항암제로서의 용도
HK1086840A (en) Benzopyranone compounds, compositions thereof, and methods for treating or preventing cancer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1086840

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090204

Termination date: 20091116

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1086840

Country of ref document: HK